CordenPharma extends Moderna deal to supply lipids to produce Covid vaccine

"This expansion will increase supply of lipid excipients used to manufacture our mRNA products," Moderna's chief technical operations and quality officer, Juan Andres, said
Pharmaceutical company CordenPharma has extended its agreement with Moderna Inc to supply large volumes of lipids used to produce Moderna's Covid-19 vaccine candidate.

The expanded agreement will be effective immediately to help meet Moderna's increasing demand over the coming months, the Reuters reported.

"This expansion will increase supply of lipid excipients used to manufacture our mRNA products," Moderna's chief technical operations and quality officer, Juan Andres, said.


Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel